Our previous study illustrated that nuclear factor IX (NFIX) promotes glioblastoma (GBM) progression by inducing migration and proliferation of GBM cells. However, the underlying mechanism of how NFIX regulates GBM cell proliferation remains obscure. In this study, we uncovered that Go-Ichi-Ni-San 1 (GINS1) is upregulated and positively correlated with NFIX in human GBM specimen. NFIX silencing downregulates the expression of GINS1, which is pivotal for cell-cycle progression and proliferation of GBM cells. Replenishment of GINS1 largely rescues the NFIX-null effect on GBM cell proliferation. Mechanistic investigation revealed that NFIX transcriptionally actives GINS1 expression by directly binding to promoter region (-1779 to -1793bp) of the GINS1 gene. Furthermore, knockdown of NFIX sensitizes GBM cells to DNA damage-inducing agents including doxorubicin and temozolomide, in a GINS1-dependent manner. Implications: Our study highlights that targeting NFIX–GINS1 axis could be a novel and potential therapeutic approach for GBM treatment.
S1. Full images of immunoblotting. S2. NFIX knockdown has no effect on p53 and p21 expression. S3. Knockdown of GINS1 by shRNAs in U87 cells. S4. Knockdown of GINS1 represses proliferation of GL261 cells S5. GINS1 rescues the delayed growth of NFIX-null GL261 tumor. S6. NFIX directly up-regulated GINS1 gene by occupying its promoter
S1. Full images of immunoblotting. S2. NFIX knockdown has no effect on p53 and p21 expression. S3. Knockdown of GINS1 by shRNAs in U87 cells. S4. Knockdown of GINS1 represses proliferation of GL261 cells S5. GINS1 rescues the delayed growth of NFIX-null GL261 tumor. S6. NFIX directly up-regulated GINS1 gene by occupying its promoter
Our previous study illustrated that nuclear factor IX (NFIX) promotes glioblastoma (GBM) progression by inducing migration and proliferation of GBM cells. However, the underlying mechanism of how NFIX regulates GBM cell proliferation remains obscure. In this study, we uncovered that Go-Ichi-Ni-San 1 (GINS1) is upregulated and positively correlated with NFIX in human GBM specimen. NFIX silencing downregulates the expression of GINS1, which is pivotal for cell-cycle progression and proliferation of GBM cells. Replenishment of GINS1 largely rescues the NFIX-null effect on GBM cell proliferation. Mechanistic investigation revealed that NFIX transcriptionally actives GINS1 expression by directly binding to promoter region (-1779 to -1793bp) of the GINS1 gene. Furthermore, knockdown of NFIX sensitizes GBM cells to DNA damage-inducing agents including doxorubicin and temozolomide, in a GINS1-dependent manner.Implications:Our study highlights that targeting NFIX–GINS1 axis could be a novel and potential therapeutic approach for GBM treatment.
S1. Full images of immunoblotting. S2. NFIX knockdown has no effect on p53 and p21 expression. S3. Knockdown of GINS1 by shRNAs in U87 cells. S4. Knockdown of GINS1 represses proliferation of GL261 cells S5. GINS1 rescues the delayed growth of NFIX-null GL261 tumor. S6. NFIX directly up-regulated GINS1 gene by occupying its promoter